EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Qβ bacteriophage nanoparticle contributes to the adjuvanticity of antiglycan vaccines through a unique inflammatory pathway

Kenna Nagy iD, Jeffery Noble, Shenglou Deng, Robert Hincapie, Anne Costanzo, Lisa Kain, Paul B Savage, M G Finn, Luc Teyton

The Journal of Immunology · 2026

DOI: 10.1093/jimmun/vkag252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2026. Verfasst von Kenna Nagy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, United States. Hauptthemen laut MEDLINE: Adjuvants, Immunologic, Polysaccharides, Nanoparticles, Allolevivirus. Die Arbeit nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health and National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current glycoconjugate vaccines often fail to induce durable B cell memory or to provide sufficiently high-affinity antibodies limiting their utility for prophylactic protection against most bacterial and fungal pathogens. We address this limitation by engineering a chemically functionalized protein nanoparticle vaccine capable of eliciting protective nanomolar affinity antiglycan antibodies and long-term humoral memory. This platform incorporates a combination of two B cell–focused adjuvants, a TLR7 agonist and a natural killer T cell agonist, in order to enhance the antiglycan antibody maturation and memory formation. To define the contributions of each pathway, the antiglycan responses were evaluated at early and late time points following immunization. Although mice deficient in both TLR7 and natural killer T cell signaling revealed diminished primary immunization responses, an unexpectedly robust antiglycan antibody titer still developed and persisted for at least 1 yr after a two-dose immunization. These results indicate that durable antiglycan humoral immunity can develop independent of the chosen adjuvant pathways and may be driven by intrinsic adjuvanticity of the recombinant bacteriophage nanoparticle. Mechanistically, this effect was associated with an inflammatory response in which IFNγ and IL-1α appeared to play important roles. Together, these findings identify a previously unappreciated component contributing to long-term antiglycan immunity and support the use of bacteriophage-derived nanoparticles as platforms for vaccines against emerging antibiotic-resistant microorganisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adjuvants, ImmunologicPolysaccharidesNanoparticlesAllolevivirusAdjuvants, VaccineAnimalsMiceNanovaccinesProtein Subunit VaccinesImmunologic MemoryMice, Inbred C57BLImmunity, HumoralInflammationFemaleToll-Like Receptor Agonists

Stichwörter der Autor:innen

adjuvantinnate sensingvaccinevirus-like particle

Substanzen

Adjuvants, ImmunologicPolysaccharidesNanovaccinesProtein Subunit VaccinesAdjuvants, VaccineToll-Like Receptor Agonists

Autor:innen und Institutionen

  • Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, United States.
  • Parker H. Petit Institute of Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, United States.
  • Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, United States.
  • School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, United States.
  • School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, United States.

ORCID-Profile: Kenna Nagy

Förderung

  • National Institutes of Health and National Institute of Allergy and Infectious Diseases

Zitieren

APA

Nagy, K., Noble, J., Deng, S., Hincapie, R., Costanzo, A., Kain, L., Savage, P. B., Finn, M. G., & Teyton, L. (2026). The Qβ bacteriophage nanoparticle contributes to the adjuvanticity of antiglycan vaccines through a unique inflammatory pathway. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkag252

Vancouver

Nagy K, Noble J, Deng S, Hincapie R, Costanzo A, Kain L, et al. The Qβ bacteriophage nanoparticle contributes to the adjuvanticity of antiglycan vaccines through a unique inflammatory pathway. The Journal of Immunology. 2026. doi:10.1093/jimmun/vkag252

BibTeX
@article{Nagy2026,
  author = {Nagy, Kenna and Noble, Jeffery and Deng, Shenglou and Hincapie, Robert and Costanzo, Anne and Kain, Lisa and Savage, Paul B and Finn, M G and Teyton, Luc},
  title = {The Qβ bacteriophage nanoparticle contributes to the adjuvanticity of antiglycan vaccines through a unique inflammatory pathway},
  journal = {The Journal of Immunology},
  year = {2026},
  doi = {10.1093/jimmun/vkag252}
}
Kostenlos starten →